Maurizio Rossini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2246994/publications.pdf

Version: 2024-02-01

344 papers 11,391 citations

24978 57 h-index 49773 87 g-index

359 all docs

359 docs citations

359 times ranked

11040 citing authors

#	Article	IF	CITATIONS
1	Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. American Journal of Medicine, 2011, 124, 1043-1050.	0.6	446
2	Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis International, 2006, 17, 914-921.	1.3	253
3	Involvement of WNT/ \hat{I}^2 -catenin Signaling in the Treatment of Osteoporosis. Calcified Tissue International, 2013, 93, 121-132.	1.5	204
4	Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis International, 2009, 20, 239-244.	1.3	198
5	Guidelines for the management of osteoporosis and fragility fractures. Internal and Emergency Medicine, 2019, 14, 85-102.	1.0	198
6	Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW). Journal of Bone and Mineral Research, 2014, 29, 487-493.	3.1	192
7	Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study. Journal of Bone and Mineral Research, 2004, 20, 758-763.	3.1	191
8	Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo, 2016, 68, 1-39.	0.4	181
9	Relationship Between Lipids and Bone Mass in 2 Cohorts of Healthy Women and Men. Calcified Tissue International, 2004, 74, 136-142.	1.5	159
10	Effects of Oral Alendronate in Elderly Patients with Osteoporosis and Mild Primary Hyperparathyroidism. Journal of Bone and Mineral Research, 2001, 16, 113-119.	3.1	157
11	Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Research and Therapy, 2010, 12, R216.	1.6	156
12	Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. Journal of Bone and Mineral Research, 2012, 27, 645-653.	3.1	143
13	Site-Specific Effects of Strength Training on Bone Structure and Geometry of Ultradistal Radius in Postmenopausal Women. Journal of Bone and Mineral Research, 1999, 14, 120-124.	3.1	142
14	The obesity paradox and osteoporosis. Eating and Weight Disorders, 2018, 23, 293-302.	1.2	142
15	Fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20–80 year-old Italian population. Clinical Nutrition, 2008, 27, 87-94.	2.3	138
16	Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2012, 50, 1288-1293.	1.4	129
17	Intravenous Neridronate in Adults With Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2003, 18, 126-130.	3.1	122
18	Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology, 2013, 52, 534-542.	0.9	122

#	Article	IF	CITATIONS
19	Vitamin D status in patients with chronic plaque psoriasis. British Journal of Dermatology, 2012, 166, 505-510.	1.4	120
20	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis showsÂunique features versus other indolent SM. Journal of Allergy and Clinical Immunology, 2014, 133, 520-528.e5.	1.5	118
21	Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes. Frontiers in Public Health, 2021, 9, 736665.	1.3	108
22	Determinants of Bone Turnover Markers in Healthy Premenopausal Women. Calcified Tissue International, 2008, 82, 341-347.	1.5	102
23	Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptaseÂlevels. Journal of Allergy and Clinical Immunology, 2015, 136, 135-139.	1.5	102
24	Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone, 2008, 42, 267-270.	1.4	99
25	Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 1994, 9, 1833-1837.	3.1	96
26	Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone, 2011, 49, 880-885.	1.4	95
27	Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporosis International, 2007, 18, 211-219.	1.3	89
28	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
29	Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. Journal of Bone and Mineral Research, 2012, 27, 2259-2263.	3.1	87
30	Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women. Osteoporosis International, 2012, 23, 2863-2871.	1.3	86
31	The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1555-1559.	1.8	82
32	Failure to perceive increased risk of fracture in women 55Âyears and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporosis International, 2011, 22, 27-35.	1.3	79
33	Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone, 2004, 35, 771-776.	1.4	77
34	An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Annals of the Rheumatic Diseases, 2013, 72, 911-917.	0.5	76
35	Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatology International, 2014, 34, 659-664.	1.5	76
36	Osteoporosis in Rheumatic Diseases. International Journal of Molecular Sciences, 2019, 20, 5867.	1.8	76

3

#	Article	IF	Citations
37	Prevalence of Sarcopenia Based on Different Diagnostic Criteria Using DEXA and Appendicular Skeletal Muscle Mass Reference Values in an Italian Population Aged 20 to 80. Journal of the American Medical Directors Association, 2013, 14, 507-512.	1.2	74
38	Limb fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20–80 year-old italian population. Clinical Nutrition, 2012, 31, 506-511.	2.3	73
39	Bone Involvement and Osteoporosis in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 383-396.	0.7	72
40	Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. Journal of Endocrinological Investigation, 2015, 38, 817-825.	1.8	70
41	Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. Bone, 2007, 40, 1073-1077.	1.4	69
42	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. Endocrine, 2016, 51, 211-221.	1.1	69
43	Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I. Calcified Tissue International, 2013, 93, 448-452.	1.5	68
44	Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporosis International, 2014, 25, 85-95.	1.3	66
45	Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone, 1994, 15, 415-417.	1.4	64
46	Physical Activity and Bone Turnover Markers: A Cross-Sectional and a Longitudinal Study. Calcified Tissue International, 2008, 83, 388-392.	1.5	64
47	Transdermal estradiol in the treatment of postmenopausal bone loss. Bone and Mineral, 1989, 7, 79-86.	2.0	63
48	Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone, 2012, 50, 739-742.	1.4	63
49	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	1.1	63
50	Definition of a population-specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS). Osteoporosis International, 2003, 14, 978-982.	1.3	62
51	Bone turnover markers in patients with osteogenesis imperfecta. Bone, 2004, 34, 1013-1016.	1.4	62
52	Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis. Clinical Rheumatology, 2018, 37, 987-997.	1.0	62
53	Short-Term Effects on Bone Turnover Markers of a Single High Dose of Oral Vitamin D ₃ . Journal of Clinical Endocrinology and Metabolism, 2012, 97, E622-E626.	1.8	61
54	Long-Term Effects of Amino-Bisphosphonates on Circulating γδT Cells. Calcified Tissue International, 2012, 91, 395-399.	1.5	61

#	Article	IF	Citations
55	Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporosis International, 2016, 27, 2411-2421.	1.3	61
56	Hip fractures in Italy: 2000–2005 extension study. Osteoporosis International, 2010, 21, 1323-1330.	1.3	60
57	Effect of aging on trabecular and compact bone components of proximal and ultradistal radius. Osteoporosis International, 1996, 6, 355-360.	1.3	59
58	Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone and Mineral, 1994, 25, 75-82.	2.0	58
59	Predicting fractures in an international cohort using risk factor algorithms without BMD. Journal of Bone and Mineral Research, 2011, 26, 2770-2777.	3.1	58
60	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Realâ€Life Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
61	Sclerostin and DKK1 in Primary Hyperparathyroidism. Calcified Tissue International, 2013, 92, 324-329.	1.5	57
62	The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporosis International, 1992, 2, 180-185.	1.3	56
63	Computed radiographic absorptiometry and morphometry in the assessment of postmenopausal bone loss. Osteoporosis International, 1996, 6, 8-13.	1.3	56
64	Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporosis International, 2019, 30, 391-402.	1.3	56
65	Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study. Nutrients, 2021, 13, 219.	1.7	56
66	Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas, 1993, 17, 191-196.	1.0	54
67	Bone Measurements in Asymptomatic Primary Hyperparathyroidism. Bone, 1998, 22, 565-570.	1.4	52
68	Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients. Calcified Tissue International, 2017, 101, 17-23.	1.5	52
69	Association of CTR and COLIA1 Alleles with BMD Values in Peri- and Postmenopausal Women. Calcified Tissue International, 2000, 67, 361-366.	1.5	51
70	Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica, 2011, 96, 482-484.	1.7	51
71	Evaluation of cortical thickness and bone density by roentgen microdensitometry in growing males and females. European Journal of Pediatrics, 1996, 155, 377-382.	1.3	50
72	Safety issues and adverse reactions with osteoporosis management. Expert Opinion on Drug Safety, 2016, 15, 321-332.	1.0	50

#	Article	IF	CITATIONS
73	The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone and Mineral, 1987, 2, 395-404.	2.0	50
74	In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clinical and Experimental Rheumatology, 2015, 33, 77-83.	0.4	50
75	Strong relationship between vitamin D status and bone mineral density in anorexia nervosa. Bone, 2015, 78, 212-215.	1.4	49
76	Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID). Annals of the Rheumatic Diseases, 2021, 80, e12-e12.	0.5	49
77	Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW). Journal of Bone and Mineral Research, 2014, 29, 260-267.	3.1	47
78	Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatology, 2014, 53, 90-94.	0.9	47
79	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes and Metabolism, 2019, 45, 347-355.	1.4	47
80	Genetic Epidemiology of Paget's Disease of Bone in Italy: sequestosome1/p62 Gene Mutational Test and Haplotype Analysis at 5q35 in a Large Representative Series of Sporadic and Familial Italian Cases of Paget's Disease of Bone. Calcified Tissue International, 2009, 84, 20-37.	1.5	46
81	Dose-Dependent Short-Term Effects of Single High Doses of Oral Vitamin D3 on Bone Turnover Markers. Calcified Tissue International, 2012, 91, 365-369.	1.5	46
82	Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis. Calcified Tissue International, 2016, 98, 438-445.	1.5	46
83	Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Annals of the Rheumatic Diseases, 2018, 77, 515-522.	0.5	46
84	Relationship of Focal Erosions, Bone Mineral Density, and Parathyroid Hormone in Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 997-1002.	1.0	45
85	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 2020, 79, 453-459.	0.5	43
86	Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology, 2021, 60, 4591-4597.	0.9	43
87	Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone, 1999, 24, 125-129.	1.4	42
88	Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). Annals of the Rheumatic Diseases, 2018, 77, 1426-1431.	0.5	42
89	Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone, 2000, 27, 119-122.	1.4	41
90	Circulating $\hat{l}^3\hat{l}'T$ cells and the risk of acute-phase response after zoledronic acid administration. Journal of Bone and Mineral Research, 2012, 27, 227-230.	3.1	41

#	Article	IF	CITATIONS
91	Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone, 2016, 92, 150-156.	1.4	40
92	Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatology International, 2016, 36, 469-482.	1.5	40
93	Low vitamin K1 intake in haemodialysis patients. Clinical Nutrition, 2017, 36, 601-607.	2.3	40
94	The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. Journal of Endocrinological Investigation, 2018, 41, 431-438.	1.8	40
95	Relationship Among VDR (Bsml and Fokl), COLIA1, and CTR Polymorphisms with Bone Mass, Bone Turnover Markers, and Sex Hormones in Men. Calcified Tissue International, 2002, 70, 457-462.	1.5	39
96	Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. Calcified Tissue International, 2016, 99, 360-364.	1.5	39
97	Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporosis International, 2013, 24, 59-67.	1.3	38
98	Traditional cardiovascular risk factors or inflammation: Which factors accelerate atherosclerosis in arthritis patients?. International Journal of Cardiology, 2017, 236, 488-492.	0.8	38
99	In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clinical Rheumatology, 2017, 36, 2377-2381.	1.0	38
100	Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. Rheumatology, 2009, 48, 773-778.	0.9	37
101	Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators. International Immunopharmacology, 2019, 67, 487-489.	1.7	37
102	International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporosis International, 2015, 26, 419-420.	1.3	36
103	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo, 2017, 69, 30.	0.4	36
104	Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk. Endocrine, 2019, 64, 367-377.	1.1	36
105	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
106	Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare. JAMA Dermatology, 2022, 158, 375.	2.0	35
107	REGULATION OF CALCIUMâ€PARATHYROID HORMONE FEEDBACK IN PRIMARY HYPERPARATHYROIDISM: EFFECTS OF BISPHOSPHONATE TREATMENT. Clinical Endocrinology, 1990, 33, 391-397.	S 1.2	34
108	Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women. Bone, 2010, 46, 244-247.	1.4	34

#	Article	IF	CITATIONS
109	Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo, 2013, 65, 143-66.	0.4	34
110	Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Rheumatology International, 2015, 35, 255-263.	1.5	34
111	Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clinical and Experimental Rheumatology, 2007, 25, 182-8.	0.4	34
112	Quantitative Ultrasound in Adults with Cystic Fibrosis: Correlation with Bone Mineral Density and Risk of Vertebral Fractures. Calcified Tissue International, 2007, 80, 44-49.	1.5	32
113	The assessment of vertebral fractures in elderly women with recent hip fractures: the BREAK Study. Osteoporosis International, 2013, 24, 1151-1159.	1.3	32
114	Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone, 2003, 33, 342-345.	1.4	31
115	Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. Osteoporosis International, 2012, 23, 2179-2188.	1.3	31
116	Zoledronic Acid in Osteoporosis Secondary toÂMastocytosis. American Journal of Medicine, 2014, 127, 1127.e1-1127.e4.	0.6	31
117	Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis. Pharmacological Research, 2019, 147, 104354.	3.1	30
118	Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210835.	1.2	30
119	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	3.1	29
120	18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity. Annals of Nuclear Medicine, 2016, 30, 430-434.	1.2	29
121	Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. Nutrients, 2020, 12, 1553.	1.7	29
122	Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study. RMD Open, 2022, 8, e002055.	1.8	29
123	Intravenous Bisphosphonate Therapy Increases Radial Width in Adults With Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2005, 20, 1323-1326.	3.1	28
124	Acute Phase Response After Zoledronic Acid is Associated with Long-Term Effects on White Blood Cells. Calcified Tissue International, 2013, 93, 249-252.	1.5	27
125	Vitamin D affects insulin sensitivity and \hat{I}^2 -cell function in obese non-diabetic youths. European Journal of Endocrinology, 2019, 181, 439-450.	1.9	27
126	New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application. Current Pharmaceutical Design, 2018, 23, 6241-6250.	0.9	27

#	Article	IF	CITATIONS
127	Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series. Calcified Tissue International, 2017, 100, 595-598.	1.5	26
128	Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone, 2019, 123, 191-195.	1.4	26
129	Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Osteoporosis International, 2020, 31, 2113-2122.	1.3	26
130	Association between exposure to fine particulate matter and osteoporosis: a population-based cohort study. Osteoporosis International, 2022, 33, 169-176.	1.3	26
131	The Volumetric Bone Density and Cortical Thickness in Adult Patients Affected by Osteogenesis Imperfecta. Journal of Clinical Densitometry, 2003, 6, 173-177.	0.5	25
132	Interferential and horizontal therapies in chronic low back pain due to multiple vertebral fractures: a randomized, double blind, clinical study. Osteoporosis International, 2007, 18, 1541-1545.	1.3	25
133	Bone Disease in Mastocytosis. Immunology and Allergy Clinics of North America, 2018, 38, 443-454.	0.7	25
134	The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions. Clinical Rheumatology, 2019, 38, 913-920.	1.0	25
135	An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. Modern Rheumatology, 2019, 29, 1059-1062.	0.9	25
136	The radiological assessment of vertebral osteoporosis. Bone, 1992, 13, S33-S36.	1.4	24
137	The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo, 2016, 68, 65-71.	0.4	24
138	Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo, 2017, 69, 9.	0.4	24
139	Interferential and horizontal therapies in chronic low back pain: a randomized, double blind, clinical study. Clinical and Experimental Rheumatology, 2006, 24, 534-9.	0.4	24
140	Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clinical and Experimental Rheumatology, 2010, 28, 561-70.	0.4	24
141	Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporosis International, 2016, 27, 3301-3307.	1.3	23
142	Depression is associated with increased disease activity and higher disability in a large Italian cohort of patients with rheumatoid arthritis. Advances in Rheumatology, 2021, 61, 57.	0.8	23
143	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
144	Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Medical Ultrasonography, 2018, 20, 177.	0.4	23

#	Article	IF	Citations
145	Radial Bending Breaking Resistance Derived by Densitometric Evaluation Predicts Femoral Neck Fracture. Osteoporosis International, 2001, 12, 864-869.	1.3	22
146	Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. Rheumatology, 2007, 46, 994-998.	0.9	22
147	Clinical development of neridronate: potential for new applications. Therapeutics and Clinical Risk Management, 2013, 9, 139.	0.9	21
148	Assessment of Fracture Risk in A Population of Postmenopausal Italian Women: A Comparison of Two Different Tools. Calcified Tissue International, 2015, 97, 50-57.	1.5	21
149	Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis. Herz, 2015, 40, 989-996.	0.4	21
150	Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis. Calcified Tissue International, 2016, 98, 580-585.	1.5	21
151	Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increased levels of vitamin K dependent proteins. Endocrine, 2016, 51, 333-341.	1.1	21
152	<scp>V</scp> itamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosa. International Journal of Eating Disorders, 2017, 50, 1041-1049.	2.1	21
153	Prognostic Role of Subclinical Left Ventricular Systolic Dysfunction Evaluated by Speckle-Tracking Echocardiography in Rheumatoid Arthritis. Journal of the American Society of Echocardiography, 2017, 30, 602-611.	1.2	21
154	Gender disparity in authorship of guidelines and recommendations in rheumatology. Annals of the Rheumatic Diseases, 2020, 79, 1122-1123.	0.5	21
155	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
156	Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients. Hypertension Research, 2020, 43, 922-928.	1.5	21
157	Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. Bone, 2014, 67, 189-192.	1.4	20
158	Medication Use Before and After Hip Fracture: A Population-Based Cohort and Case-Control Study. Drugs and Aging, 2014, 31, 547-553.	1.3	20
159	Fracture risk assessment in postmenopausal women with diabetes: comparison between DeFRA and FRAX tools. Gynecological Endocrinology, 2018, 34, 404-408.	0.7	20
160	High prevalence of occult heart disease in normotensive patients with rheumatoid arthritis. Clinical Cardiology, 2018, 41, 736-743.	0.7	20
161	Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clinical and Experimental Rheumatology, 2019, 37, 133-136.	0.4	20
162	Higher Circulating Parathormone is Associated with Smaller and Weaker Bones in Obese Children. Calcified Tissue International, 2014, 95, 1-7.	1.5	19

#	Article	lF	CITATIONS
163	Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis. Calcified Tissue International, 2016, 99, 23-29.	1.5	19
164	Capacitively Coupled Electric Field for Pain Relief in Patients with Vertebral Fractures and Chronic Pain. Clinical Orthopaedics and Related Research, 2010, 468, 735-740.	0.7	18
165	Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Design, Development and Therapy, 2013, 7, 601.	2.0	18
166	Denosumab, cortical bone and bone erosions in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, e70-e70.	0.5	18
167	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics: Targets and Therapy, 2018, Volume 12, 151-158.	3.0	18
168	Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment. Frontiers in Medicine, 2020, 7, 613720.	1.2	18
169	Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199325.	1.2	18
170	The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders. Frontiers in Endocrinology, 2021, 12, 620920.	1.5	18
171	Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission. ACR Open Rheumatology, 2021, 3, 832-833.	0.9	18
172	Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density. Calcified Tissue International, 2008, 83, 301-307.	1.5	17
173	Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease. Journal of the American Society of Echocardiography, 2016, 29, 689-698.	1.2	17
174	Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. European Journal of Preventive Cardiology, 2016, 23, 1848-1859.	0.8	16
175	Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. Clinical Rheumatology, 2018, 37, 3093-3098.	1.0	16
176	Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. Journal of Nephrology, 2019, 32, 635-643.	0.9	16
177	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	1.0	16
178	Osteoporosis Treatment: When to Discontinue and When to Re-start. Bone Research, 2013, 1, 323-335.	5.4	16
179	Treatment Thresholds for Osteoporosis and Reimbursability Criteria: Perspectives Associated with Fracture Risk-Assessment Tools. Calcified Tissue International, 2013, 93, 195-200.	1.5	15
180	Prevalence and factors related to inappropriately high left ventricular mass in patients with rheumatoid arthritis without overt cardiac disease. Journal of Hypertension, 2015, 33, 2141-2149.	0.3	15

#	Article	IF	CITATIONS
181	Dickkopf-1 and Sclerostin Serum Levels in Patients with Systemic Mastocytosis. Calcified Tissue International, 2015, 96, 410-416.	1.5	15
182	Bone metabolism in patients with anorexia nervosa and amenorrhoea. Eating and Weight Disorders, 2018, 23, 255-261.	1.2	15
183	Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. Endocrine, 2018, 59, 242-259.	1.1	15
184	Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 45-51.	0.7	15
185	Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. Calcified Tissue International, 2020, 106, 371-377.	1.5	15
186	Effect of oral vitamin D2 yearly bolus on hip fracture risk in elderly women: a community primary prevention study. Aging Clinical and Experimental Research, 2004, 16, 432-436.	1.4	14
187	Densitometric Threshold and Vertebral Fractures in Heart Transplant Patients. Transplantation, 2011, 92, 106-111.	0.5	14
188	Empirically Based Composite Fracture Prediction Model From the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 817-826.	1.8	14
189	Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Endocrine, 2015, 49, 620-627.	1.1	14
190	Declining trends in the incidence of hip fractures in people aged 65 years or over in years 2000–2011. European Journal of Internal Medicine, 2016, 35, 60-65.	1.0	14
191	Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis?. Journal of Bone and Mineral Research, 2017, 32, 2142-2143.	3.1	14
192	The use of bisphosphonates in women: when to use and when to stop. Expert Opinion on Pharmacotherapy, 2015, 16, 2409-2421.	0.9	13
193	Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study. Calcified Tissue International, 2017, 100, 341-347.	1.5	13
194	Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study. Bone, 2017, 103, 144-149.	1.4	13
195	Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: A longitudinal study. International Journal of Rheumatic Diseases, 2019, 22, 1041-1045.	0.9	13
196	Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110140.	1.2	13
197	Environmental Air Pollution Is a Predictor of Poor Response to Biological Drugs in Chronic Inflammatory Arthritides. ACR Open Rheumatology, 2021, 3, 451-456.	0.9	13
198	The Immunologic Profile of Vitamin D and Its Role in Different Immune-Mediated Diseases: An Expert Opinion. Nutrients, 2022, 14, 473.	1.7	13

#	Article	IF	CITATIONS
199	Quantitative Ultrasound Calcaneous Measurements: Normative Data for the Italian Population. The ESOPO Study. Journal of Clinical Densitometry, 2007, 10, 340-346.	0.5	12
200	The burden of previous fractures in hip fracture patients. The Break Study. Aging Clinical and Experimental Research, 2011, 23, 183-186.	1.4	12
201	Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. Journal of Allergy and Clinical Immunology, 2014, 133, 933-935.	1.5	12
202	Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates. Journal of Rheumatology, 2019, 46, 318-322.	1.0	12
203	Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. Calcified Tissue International, 2021, 108, 231-239.	1.5	12
204	Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: a case-based review. Clinical Rheumatology, 2021, 40, 2973-2977.	1.0	12
205	Vitamin D and disease severity in coronavirus disease 19 (COVID-19). Reumatismo, 2021, 72, 189-196.	0.4	12
206	The genetic background of osteoporosis in cystic fibrosis: Association analysis with polymorphic markers in four candidate genes. Journal of Cystic Fibrosis, 2006, 5, 229-235.	0.3	11
207	Once-monthly oral ibandronate in postmenopausal osteoporosis: Translation and updated review. Clinical Therapeutics, 2009, 31, 1497-1510.	1.1	11
208	Osteoporosis treatment: why ibandronic acid?. Expert Opinion on Pharmacotherapy, 2013, 14, 1371-1381.	0.9	11
209	Management of patients with complex regional pain syndrome type I. Osteoporosis International, 2016, 27, 2423-2431.	1.3	11
210	Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease. Clinical Rheumatology, 2017, 36, 2487-2495.	1.0	11
211	Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed †window of opportunity'. Annals of the Rheumatic Diseases, 2023, 82, e181-e181.	0.5	11
212	Comments on Kanis et al.: Algorithm for the management of patients at low, high, and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1015-1015.	1.3	11
213	Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset. Archives of Osteoporosis, 2021, 16, 56.	1.0	11
214	The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes. Journal of Bone and Mineral Research, 2021, 36, 2177-2183.	3.1	11
215	Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience. Clinical and Experimental Rheumatology, 2011, 29, 728-35.	0.4	11
216	Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 883-892.	1.5	10

#	Article	IF	CITATIONS
217	Cardiovascular risk stratification and management of patients with rheumatoid arthritis in clinical practice: The "EPIDAURO registry― International Journal of Cardiology, 2014, 172, 534-536.	0.8	10
218	Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone. Clinical Rheumatology, 2017, 36, 925-928.	1.0	10
219	Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis. Calcified Tissue International, 2017, 100, 40-46.	1.5	10
220	Osteoporosis: Economic Burden of Disease in Italy. Clinical Drug Investigation, 2020, 40, 449-458.	1.1	10
221	Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressiva. Journal of Bone and Mineral Research, 2010, 25, 1460-1462.	3.1	9
222	Long-Term Effects of Neridronate and its Discontinuation in Patients with Primary Hyperparathyroidism. Calcified Tissue International, 2011, 89, 21-28.	1.5	9
223	Vitamin D and rheumatic diseases. Reumatismo, 2014, 66, 153-170.	0.4	9
224	Serum Levels of Tryptase Suggest That Mast Cells Might Have an Antiinflammatory Role in Rheumatoid Arthritis: Comment on the Article by Rivellese et al. Arthritis and Rheumatology, 2016, 68, 769-769.	2.9	9
225	Effects of denosumab on peripheral lymphocyte subpopulations. Endocrine, 2016, 53, 857-859.	1.1	9
226	Self-perception of fracture risk: what can it tell us?. Osteoporosis International, 2017, 28, 3495-3500.	1.3	9
227	Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo, 2017, 69, 105.	0.4	9
228	A multi-dimensional questionnaire quantifying quality of life in elderly osteoporotic women: the Italian Triple-Q Osteoporosis Study. Aging Clinical and Experimental Research, 2010, 22, 330-339.	1.4	8
229	Allergy and the bone: unexpected relationships. Annals of Allergy, Asthma and Immunology, 2011, 107, 202-206.	0.5	8
230	Adherence to therapeutic and diagnostic recommendations in patients with femur fracture and at risk of re-fracture or death: results of an analysis of administrative databases. Reumatismo, 2012, 64, 18-26.	0.4	8
231	Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis. Patient Preference and Adherence, 2016, 10, 523.	0.8	8
232	Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. Clinical Rheumatology, 2020, 39, 727-736.	1.0	8
233	Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids. Clinical and Experimental Rheumatology, 2009, 27, 567-73.	0.4	8
234	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients, 2022, 14, 1742.	1.7	8

#	Article	IF	CITATIONS
235	Trunk and Lower Limb Fat Mass Evaluated by Dual-Energy X-Ray Absorptiometry in a 20- to 80-Year-Old Healthy Italian Population. Annals of Nutrition and Metabolism, 2012, 61, 151-159.	1.0	7
236	Duration of treatment for osteoporosis. Reumatismo, 2013, 65, 22-35.	0.4	7
237	Insight into the WNT system and its drug related response. Reumatismo, 2013, 65, 219-30.	0.4	7
238	Can Febuxostat Reduce Triglyceride and Cholesterol Serum Levels in Gouty Patients?. Journal of Clinical Rheumatology, 2014, 20, 394-395.	0.5	7
239	The relationship between the Spine Deformity Index, biochemical parameters of bone metabolism and vascular calcifications: results from the Epidemiological VERtebral FRACtures iTalian Study (EVERFRACT) in dialysis patients. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1595-603.	1.4	7
240	Prevalence and Factors Associated with Subclinical Left Ventricular Systolic Dysfunction Evaluated by Midâ€Wall Mechanics in Rheumatoid Arthritis. Echocardiography, 2016, 33, 1290-1299.	0.3	7
241	Changes in Adipose Tissue Distribution and Association between Uric Acid and Bone Health during Menopause Transition. International Journal of Molecular Sciences, 2019, 20, 6321.	1.8	7
242	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. Cancers, 2019, 11, 30.	1.7	7
243	Relationship Between Increased Fecal Calprotectin Levels and Interstitial Lung Disease in Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 274-278.	1.0	7
244	Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. Annals of the Rheumatic Diseases, 2020, 79, e150-e150.	0.5	7
245	Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo, 2020, 72, 71-74.	0.4	7
246	Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells. Journal of Bone and Mineral Research, 2019, 34, 570-571.	3.1	7
247	Golimumab: A Novel Anti-Tumor Necrosis Factor. Biologics in Therapy, 2013, 3, 83-107.	1.8	6
248	Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy. Reumatismo, 2013, 65, 113-20.	0.4	6
249	CD14++ CD16 \hat{a} ° monocytes are the main source of $11\hat{l}^2$ -HSD type 1 after IL-4 stimulation. International Immunopharmacology, 2017, 43, 156-163.	1.7	6
250	Vitamin D: no efficacy without deficiency. What's new?. Reumatismo, 2019, 71, 57-61.	0.4	6
251	Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment. Frontiers in Medicine, 2020, 7, 551.	1.2	6
252	Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis. Expert Opinion on Biological Therapy, 2020, 20, 787-798.	1.4	6

#	Article	IF	CITATIONS
253	Vitamin D supplementation: much ado about nothing. Gynecological Endocrinology, 2020, 36, 185-189.	0.7	6
254	Predictors and prognostic role of low myocardial mechano-energetic efficiency in chronic inflammatory arthritis. Journal of Hypertension, 2021, 39, 53-61.	0.3	6
255	Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. Clinical Rheumatology, 2022, 41, 1247-1254.	1.0	6
256	Evidence of Sustained Vertebral and Nonvertebral Antifracture Efficacy with Ibandronate Therapy: A Systematic Review. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 67-79.	1.2	5
257	Three-Year Prospective Study on Fracture Risk in Postmenopausal Women by Quantitative Ultrasound at the Phalanges. Journal of Clinical Densitometry, 2013, 16, 341-346.	0.5	5
258	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo, 2014, 66, 285-303.	0.4	5
259	A Rapid Skeletal Turnover in Radiographic Mimic of Osteopetrosis Might Be Secondary to Systemic Mastocytosis. Journal of Bone and Mineral Research, 2015, 30, 945-945.	3.1	5
260	Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment. Rheumatology International, 2015, 35, 735-739.	1.5	5
261	Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. Clinical Case Reports (discontinued), 2017, 5, 1988-1991.	0.2	5
262	Rheumatoid arthritis, $\hat{I}^3\hat{I}$ T cells and bisphosphonates. Annals of the Rheumatic Diseases, 2018, 77, e57-e57.	0.5	5
263	Radiological features of knee joint synovial chondromatosis. Reumatismo, 2019, 71, 81-84.	0.4	5
264	Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. Internal and Emergency Medicine, 2021, 16, 863-874.	1.0	5
265	Effect of neridronate in osteopenic patients after heart, liver or lung transplant: a multicenter, randomized, double-blind, placebo-controlled study. Panminerva Medica, 2021, 63, 214-223.	0.2	5
266	Evaluation of cortical thickness and bone density by roentgen microdensitometry in growing males and females. European Journal of Pediatrics, 1996, 155, 377-382.	1.3	5
267	Instrumental diagnosis of osteoporosis. Aging Clinical and Experimental Research, 1998, 10, 240-248.	1.4	4
268	Lack of Effect of Teriparatide on Joint Erosions in Rheumatoid Arthritis Is an Expected Result: Comment on the Article by Solomon et al. Arthritis and Rheumatology, 2018, 70, 475-476.	2.9	4
269	Incidence and predictors of new onset left ventricular diastolic dysfunction in asymptomatic patients with rheumatoid arthritis without overt cardiac disease. Monaldi Archives for Chest Disease, 2019, 89, .	0.3	4
270	Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al. Annals of the Rheumatic Diseases, 2020, 79, e166-e166.	0.5	4

#	ARTICLE Correspondence on a€ Characteristics associated with hospitalisation for COVID-19 in people with	IF	Citations
271	rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryâ∈™ by Gianfrancesco <i>et al</i> i>et al i>n Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases. Annals of the Rheumatic	0.5	4
272	Economic Burden of Osteoporotic Patients with Fracture: Effect of Treatment With or Without Calcium/Vitamin D Supplements , Nutrition and Dietary Supplements , 2020, Volume 12, 21-30.	0.7	4
273	Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 158.	1.6	4
274	Cost of osteoporosis-related fracture in Italy. Results of the BLOCK study. Farmeconomia E Percorsi Terapeutici, 2011, 12, 99-105.	0.2	4
275	Magnetic resonance imaging at 3.0-T in postmenopausal osteoporosis: a prospective study and review of the literature. Radiologia Brasileira, 2022, 55, 216-224.	0.3	4
276	A case of mandible Paget's disease of the bone treated with intravenous neridronate. Reumatismo, 2016, 68, 154-158.	0.4	3
277	Could $\hat{I}^3/\hat{I}^{'}T$ Cells Explain Adverse Effects of Zoledronic Acid? Comment on the Article by Reinhardt et al. Arthritis and Rheumatology, 2017, 69, 1339-1339.	2.9	3
278	Anti-CCP antibodies and bone. Arthritis Research and Therapy, 2018, 20, 63.	1.6	3
279	Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis. Scandinavian Journal of Rheumatology, 2020, 49, 389-396.	0.6	3
280	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. Journal of Rheumatology, 2020, 47, 796-808.	1.0	3
281	Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. International Journal of Rheumatic Diseases, 2020, 23, 681-692.	0.9	3
282	Disease Activity and Anticitrullinated Peptide Antibody Positivity Predict the Worsening of Ventricular Function in Rheumatoid Arthritis. ACR Open Rheumatology, 2020, 2, 232-241.	0.9	3
283	Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis. Frontiers in Cardiovascular Medicine, 2021, 8, 676076.	1.1	3
284	Calcium and vitamin D supplementation: when and why. Minerva Obstetrics and Gynecology, 2021, 73, 704-713.	0.5	3
285	The Potential Impact of Inducing a Restriction in Reimbursement Criteria on Vitamin D Supplementation in Osteoporotic Patients with or without Fractures. Nutrients, 2022, 14, 1877.	1.7	3
286	Skeletal implications of isolated bone marrow mastocytosis (reply): Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis (reply). Haematologica, 2011, 96, e28-e28.	1.7	2
287	Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritides. Advances in Therapy, 2014, 31, 780-802.	1.3	2
288	The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study. Reumatismo, 2016, 68, 188-194.	0.4	2

#	Article	IF	Citations
289	Densitometric evaluation might prevent failure of knee artroplasty for aseptic loosening. Journal of King Abdulaziz University, Islamic Economics, 2016, 37, 212-214.	0.5	2
290	Disease activity and left ventricular systolic function in rheumatoid arthritis: TableÂ1. Annals of the Rheumatic Diseases, 2016, 75, e83-e83.	0.5	2
291	Regional Differences in Incident Prefrailty and Frailty. Journal of Women's Health, 2017, 26, 992-998.	1.5	2
292	Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis Research and Therapy, 2018, 20, 233.	1.6	2
293	Are aortic coarctation and rheumatoid arthritis different models of aortic stiffness? Data from an echocardiographic study. Cardiovascular Ultrasound, 2018, 16, 9.	0.5	2
294	Objective evaluation of the response of infantile haemangiomas to propranolol treatment using a threeâ€dimensional imaging system. British Journal of Dermatology, 2019, 181, 836-838.	1.4	2
295	Usefulness of CHA2DS2â€VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2020, 23, 106-115.	0.9	2
296	Could Previous Exposure to Nitrogen ontaining Bisphosphonates Mitigate Friendly Fire?. Journal of Bone and Mineral Research, 2020, 35, 2082-2082.	3.1	2
297	Dietary calcium intake in a cohort of individuals evaluated for low bone mineral density: a multicenter Italian study. Aging Clinical and Experimental Research, 2021, , 1.	1.4	2
298	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. Minerva Medica, 2021, 112, 246-254.	0.3	2
299	Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study. Nutrients, 2021, 13, 2293.	1.7	2
300	Efficacy of mud plus bath therapy as compared to bath therapy in osteoarthritis of hands and knees: a pilot single-blinded randomized controlled trial. Reumatismo, 2021, 73, .	0.4	2
301	Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 241-246.	0.4	2
302	Acute Phase Reaction and Fracture Risk Reduction: Are Gamma-Delta T Cells and Hypovitaminosis D the Missing Link?. Journal of Bone and Mineral Research, 2020, 37, 1622-1622.	3.1	2
303	Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211050.	1.2	2
304	Clinical Utility of a Wheat-Germ Precipitation Assay for Determination of Bone Alkaline Phosphatase Concentrations in Patients with Different Metabolic Bone Diseases. Clinical Chemistry and Laboratory Medicine, 1995, 33, 433-9.	1.4	1
305	AB0285â€Correlation between serum levels of parathyroid hormone and DICKKOPF-1 in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 654.1-654.	0.5	1
306	AB0436â€Persistence of Clinical Remission by a Decreased Treatment Regimen of 4 MG/KG Intravenous Tocilizumab: A Randomized Clinical Trial. Annals of the Rheumatic Diseases, 2015, 74, 1040.3-1040.	0.5	1

#	Article	IF	CITATIONS
307	AB0776â€18F-Fluoride PET/CT for Detection of Axial Involvement in Ankylosing Spondylitis:. Annals of the Rheumatic Diseases, 2015, 74, 1158.2-1158.	0.5	1
308	DXA bone mineral density in males: retrospective study in real life. Aging Clinical and Experimental Research, 2015, 27, 425-430.	1.4	1
309	AB0313â€Short-Term Effects of Tnf Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis:. Annals of the Rheumatic Diseases, 2016, 75, 1007.2-1008.	0.5	1
310	FRIO485â€In peripheral psoriatic arthritis DKK-1 and pth are lower than in rheumatoid arthritis and healthy controls. , 2017, , .		1
311	Tuberculosis Infection Despite Isoniazid Prophylaxis in a Patient With Psoriatic Arthritis Treated With Etanercept. Journal of Clinical Rheumatology, 2019, 25, e74-e75.	0.5	1
312	Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system $\hat{a} \in \text{``An overlooked association'?}$. European Journal of Internal Medicine, 2020, 80, 106-107.	1.0	1
313	Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction. Internal and Emergency Medicine, 2021, 16, 73-81.	1.0	1
314	POS0675â€THE COMPARATIVE 3-YEAR RETENTION RATE OF TARGETED-SYNTHETIC AND BIOLOGIC DRUGS FOR RHEUMATOID ARTHRITIS: REAL-LIFE DATA FROM THE ITALIAN GISEA REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 582.1-582.	0.5	1
315	Response to: â€ [*] Correspondence on â€ [*] Gender disparity in authorship of guidelines and recommendations in rheumatologyâ€ [™] â€ [™] by Stewart et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219305.	0.5	1
316	Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction. Clinical and Experimental Rheumatology, 2020, 38, 420-427.	0.4	1
317	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. Clinical and Experimental Rheumatology, 2021, 39, 344-350.	0.4	1
318	Paradoxical Raynaud's phenomenon following iloprost infusion in a patient with systemic sclerosis. Scandinavian Journal of Rheumatology, 0, , 1-2.	0.6	1
319	Terapia dell'osteogenesi imperfetta. L Endocrinologo, 2008, 9, 28-34.	0.0	0
320	SATO415â€Effects of Intra-Articular Clodronate in the Treatment of Knee Osteoarthritis: Results of A Double-Blind, Randomised Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 2014, 73, 745.1-745.	0.5	0
321	SATO112â€Cardiovascular Risk in Rheumatoid Arthritis Patients: Subclinical Left Ventricular Systolic Dysfunction in Asymptomatic Patients. Annals of the Rheumatic Diseases, 2015, 74, 691.1-691.	0.5	0
322	AB0684â€Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis: Table 1. Annals of the Rheumatic Diseases, 2015, 74, 1126.3-1127.	0.5	0
323	Efficacité et Tolérance du Baricitinib Chez les Patients Atteints de Polyarthrite RhumatoÃ⁻de Active et Présentant une Réponse Inadéquate Aux csDMARDsÂ: Résumé des Résultats de L'étude de Pl Semaines RA-BUILD. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A126-A127.	ന ങ്ങ 3 de	2 0
324	Silvano Adami. Journal of Bone and Mineral Research, 2016, 31, 1123-1123.	3.1	0

#	Article	IF	Citations
325	AB0761â€SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN REAL LIFE: AN ITALIAN EXPERIENCE. 2019, , .	,,	O
326	FRIO469â€CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN. , 2019, , .		0
327	FRIOO45â€CHANGES IN LEFT VENTRICULAR SYSTOLIC FUNCTION ARE PREDICTED BY DISEASE SEVERITY IN PATIENTS WITH RHEUMATOID ARTHRITISWITHOUT PRIOR CARDIOVASCULAR DISEASE., 2019, , .		0
328	AB0831â€PERSPECTIVE ON THE CLINICAL PRACTICE MANAGEMENT OF HYPOVITAMINOSIS D FROM A MEETING OF ITALIAN EXPERTS. , 2019, , .	ı	0
329	THU0557â€NERVE GROWTH FACTOR, SCLEROSTIN AND DKK-1 SERUM LEVELS IN COMPLEX REGIONAL PAIN SYNDROME1 (CRPS-1): A PILOT STUDY ON 41 PATIENTS. , 2019, , .		O
330	AB0641â€VITAMIN D SERUM LEVELS AND THE RISK OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A LONGITUDINAL STUDY. , 2019, , .		0
331	AB0370â€EFFICACY AND SAFETY OF BIOLOGIC TREATMENT IN ELDERLY RHEUMATOID ARTHRITISPATIENTS: A WIDE COHORT STUDY. , 2019, , .		O
332	Comment on: Association between environmental air pollution and rheumatoid arthritis flares: reply. Rheumatology, 2021, 60, e341-e341.	0.9	0
333	Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2021, 24, 510-518.	0.9	O
334	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. Arthritis Research and Therapy, 2021, 23, 89.	1.6	0
335	POS0218â€TUMOR-NECROSIS FACTOR INHIBITORS IMPROVE AORTIC STIFFNESS IN PATIENTS WITH LONGSTANDING RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 326.2-327.	0.5	O
336	SATO311â€Prevalence and factors related to inappropriately high left ventricular mass in patients with psoriatic arthritis without overt cardiac disease. , 2018, , .		0
337	FRI0017â€An exploratory study on the role of vitamin d supplementation in improving pain and disease activity in rheumatoid arthritis. , 2018, , .		0
338	AB0893â€THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJEC - A RANDOMIZED OPEN-LABEL PARALLEL GROUP STUDY Annals of the Rheumatic Diseases, 2020, 79, 1750.2-1751.	TS 0.5	0
339	AB1094â€SCAR IMAGING ECHOCARDIOGRAPHY WITH ULTRASOUND MULTI-PULSE SCHEME [eSCAR] FOR THE DETECTION OF MYOCARDIAL FIBROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS Annals of the Rheumatic Diseases, 2020, 79, 1836.2-1836.	0.5	O
340	The initiative on hip fractures of the Veneto Region. Clinical Cases in Mineral and Bone Metabolism, 2012, 9, 45-9.	1.0	0
341	Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Clinical and Experimental Rheumatology, 2017, 35, 548.	0.4	O
342	Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study. Clinical and Experimental Rheumatology, 2021, 39, 344-350.	0.4	0

#	Article	IF	CITATIONS
343	Real-world Coronavirus disease-19 vaccine hesitancy in systemic sclerosis. Clinical and Experimental Rheumatology, 0, , .	0.4	O
344	Real-world Coronavirus disease-19 vaccine hesitancy in systemic sclerosis Clinical and Experimental Rheumatology, 2022, , .	0.4	0